◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW MEDIUM

Vyvanse

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

Cleanest amphetamine PK on the market and lower IV/intranasal abuse liability than IR Adderall, but oral abuse profile is similar to dexamphetamine and the brain-development concern at age 20 (PFC dopamine axon misrouting in male adolescent rodents — replicated 2023-2025) applies equally. 12-14hr duration also collides with Dylan's late-chronotype migration (evening anxiety + sleep onset push). Verdict flips to STRONG-CANDIDATE only with formal ADHD or BED diagnosis warranting Rx.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Same brain-development concern as Adderall — adolescent male amphetamine exposure misroutes mesolimbic dopamine axons to PFC (Reynolds 2023, replicated 2025) and the prodrug delivery doesn't change which active molecule reaches the brain. The 12-14hr duration creates an additional collision with late-chronotype sleep migration: a 9 AM dose is still active at 9 PM, making midnight bedtime targets fragile. Modafinil 100mg AM 5-6×/week is the better tool for this archetype — same cognitive workload coverage, much lower brain-dev concern, no schedule II hassle, gray-market sourcing solved. Verdict flips to STRONG-CANDIDATE with formal ADHD diagnosis — at that point the calculus is treatment of disorder vs. baseline-enhancement, and Vyvanse is the cleanest amphetamine option.

  • 30-50, executive maintenance
    OPTIONAL

    ADD if ADHD-diagnosed. Brain-dev concern far less relevant past age 25-26. Vyvanse's smoother PK is genuinely useful for executive workloads with long days. Cost manageable with insurance. Off-label use still risks tolerance, dependence, sleep impact — but the tradeoff is more favorable than at age 20.

  • 50+, mild cognitive decline
    SKIP

    Cardiovascular contraindications (HTN, LVH common), no evidence base in age-related cognitive decline (different mechanism than ADHD), and amphetamines may worsen cerebrovascular risk. Not a tool for this group.

  • Anxiety-prone
    SKIP

    Amphetamines exacerbate anxiety in most prone individuals. The smoother PK helps marginally vs IR amphetamine but doesn't change the fundamental NE-driven anxiety mechanism. Modafinil + L-theanine is the better path; SSRIs or buspirone primary.

  • High athletic load, tested status
    SKIP

    if WADA-tested (S6 stimulant, banned in-competition since first WADA list; out-of-competition use detectable for several days). Therapeutic Use Exemption available for documented ADHD but onerous. SKIP for tested + non-ADHD even if untested in current sport, because of training disruption: appetite suppression undercuts caloric requirements (Dylan ~3500+ kcal/day target), HR elevation corrupts heart-rate-zone training data, sleep impact compounds during training camps. Dylan is untested in competition but the *training-load* incompatibility still applies.

  • Sleep-disordered
    SKIP

    for primary insomnia. STRONG-CANDIDATE for narcolepsy with cataplexy or idiopathic hypersomnia as adjunct to first-line therapy (modafinil/sodium oxybate); LDX has off-label use in narcolepsy when modafinil/pitolisant insufficient.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    No evidence base for recovery; adverse impact on sleep (a primary recovery driver), appetite (caloric repletion), and cardiovascular load are all anti-recovery.

  • Strength/anabolic-focused
    SKIP

    Appetite suppression directly opposes bulking; no anabolic effect; potential testosterone reduction reported in chronic high-dose use (small effect). Categorically wrong tool for this archetype.

  • DylanDiagnosed ADHD adult, otherwise Dylan-like (untested, brain-priority)
    STRONG-CANDIDATE

    If formal ADHD eval results in diagnosis, Vyvanse is the cleanest amphetamine option (smoother PK, lower IV/intranasal abuse liability, FDA approval, insurance coverage). Still has brain-dev nuance at age 20 but treatment-of-disorder calculus shifts the math — untreated ADHD has its own cognitive and life-trajectory costs. Methylphenidate-class (Concerta, Focalin XR) remains the alternative with marginally lower brain-dev concern.

  • Diagnosed binge-eating disorder
    STRONG-CANDIDATE

    Only FDA-approved BED pharmacotherapy. 50-70mg AM, paired with CBT-E. Effects modest but real — binge days/week typically drop from 4-5 → <1.

▸ Subjective experience (deep)

Onset: ~60-90 minutes (slower than Adderall IR's 30-45 min — the RBC cleavage is the rate-limiting step). Some users report a "warm in" feeling around 90 minutes that builds rather than punches.

Peak: 3-4 hours post-dose. Notably lower peak intensity than IR Adderall at matched d-amphetamine exposure — flatter curve. Less "stim rush," less euphoria, less peripheral pump (HR/BP go up but more gradually).

Plateau: ~6-10 hours of clear stimulant-like focus. The "on" period feels evenly stimulating without the IR Adderall up-down oscillation.

Taper: Long, gentle taper from hour 8-14. Most users describe the comedown as much milder than Adderall — less crash, less rebound fatigue, less mood drop. Counter-intuitive trade-off: the gentler taper means the drug is still active at hour 10-12 when you'd ideally be winding down for sleep.

Characteristic effects:

  • Steady focus rather than amped energy. Productive but less "wired."
  • Suppressed appetite (often skipped lunch entirely; small, unsatisfying dinner).
  • Reduced thirst sensation (forces deliberate hydration).
  • Mood lift smaller and less euphoric than Adderall — some users describe this as "feature not bug" (less reinforcing), others as "less fun" (less motivating).
  • Talkativeness/sociability increased modestly. Not as much as Adderall.
  • Jaw tension, bruxism — present but usually less intense than IR amphetamine.
  • Increased HR (typically +10-15 bpm at clinical doses), mild BP elevation (+5-10 mmHg systolic).
  • Mild tremor at higher doses (60-70mg).
  • Evening edge / "still on" anxiety — the long tail can produce uncomfortable activation in late afternoon/evening, particularly for users with normal chronotype trying to sleep at 10-11 PM. For Dylan's late chronotype migrating to midnight, this is a problem: a 10 AM dose has him still "on" at 10 PM.

Honest variability: Many users (~30-40%) report Vyvanse is genuinely smoother and prefer it over Adderall; others (~20%) feel Vyvanse "doesn't kick in enough" because they're used to the IR peak signature. About 5-10% develop intolerable insomnia, anxiety, or HR/BP elevation requiring discontinuation. CYP2D6 status doesn't matter much (d-amphetamine isn't 2D6-cleared), but COMT and DAT1 polymorphisms predict response.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Real and clinically significant for most users on chronic daily dosing. Receptor downregulation (DAT, D1/D2) and behavioral tolerance. Smoother LDX PK doesn't prevent tolerance — same active molecule, same downstream adaptation.
  • Recommended cycle (off-label cognitive use): Weekend washouts (Sat-Sun off), or 2-3×/week max for cognitive use, or 4-6 week on / 1 week off rotation. The encyclopedia table specifies stimulants used cognitively: 2-3×/week max with 10-14 day breaks for tolerance reset.
  • Reset protocol if needed: 2-4 weeks complete washout. Severe tolerance may require longer (8+ weeks). Memantine 5-10mg/day during use has anecdotal support for slowing receptor downregulation but human evidence is thin.
  • For ADHD/BED Rx use: Daily dosing is the norm; tolerance typically manifests as gradual dose escalation requests over 12-24 months. Many adults stabilize at 50-70mg long-term without further escalation.
▸ Stacking deep dive

Synergistic with

  • memantine (5-10mg/day): May slow stimulant tolerance via NMDA antagonism. Anecdotal + small clinical signal. Useful if Vyvanse becomes part of long-term protocol.
  • l-tyrosine (PRN): Substrate for catecholamine synthesis. Some users report less crash and less tolerance buildup with intermittent tyrosine support. Low-evidence but mechanistically plausible.
  • magnesium glycinate (Dylan's V4 covers this): Helps with bruxism, sleep, BP modulation.
  • l-theanine (Dylan's V4 covers this): Smooths the adrenergic edge, may reduce anxiety on dose days.
  • omega-3 / DHA (Dylan's V4 covers this): General neuroprotection during stimulant exposure.
  • NAC (Dylan's V4 covers this): Glutathione support, mild glutamatergic modulation. Some evidence for reducing stimulant abuse-related craving in cocaine/methamphetamine populations; weaker for therapeutic amphetamine.

Avoid stacking with

  • MAO inhibitors (non-selective: tranylcypromine, phenelzine): Hypertensive crisis risk. Hard contraindication.
  • Selegiline >10mg/day: Loses MAO-B selectivity → same hypertensive crisis risk. Low-dose selegiline (1-2.5mg) is safer but always with caution and monitoring.
  • SSRIs/SNRIs/triptans/tramadol: Serotonin syndrome risk. Manageable with monitoring but real.
  • Other stimulants (modafinil, methylphenidate, caffeine high-dose): Stacked cardiovascular load; no additional cognitive benefit; receptor saturation. The encyclopedia explicitly flags Vyvanse + Dexedrine as a "stim + stim" combination to avoid.
  • TAK-653, AMPA-positive modulators near peak: Theoretical glutamatergic stacking risk; insufficient data, default to caution.
  • Phenibut and GABAergic depressants: Defeats the stimulant; risk of binge-cycle pattern.

Neutral / safe co-administration

  • All Dylan's V4 supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no interactions known.
  • Creatine — neutral.
  • Most peptides Dylan is using/planning (Semax, Selank, Adamax, BPC-157, TB-500) — neutral.
  • Russian nootropics (bromantane, picamilon) — neutral pharmacokinetically; clinical stacking unstudied.
▸ Drug interactions deep dive

Lisdexamfetamine metabolic profile:

  • Activation: RBC cytosolic metallo-aminopeptidase (rate-limiting). Not CYP-dependent, not GI peptidase-dependent.
  • Active metabolite (d-amphetamine): Cleared via CYP2D6 (minor), MAO (minor), urinary excretion (major, especially under acidic urine pH).
  • Urinary pH dependence: Acidic urine (pH <6) increases d-amphetamine clearance dramatically (half-life shortens to ~7hr); alkaline urine (pH >7) extends half-life to 19+ hr. Vitamin C, citric foods, ammonium chloride lower urinary pH; sodium bicarbonate raises it.

Clinically significant interactions:

1. MAO inhibitors — HARD CONTRAINDICATION

  • Tranylcypromine, phenelzine, isocarboxazid, linezolid, methylene blue. Risk of hypertensive crisis. Wait ≥14 days after stopping MAOI before starting LDX. Selegiline at MAO-B-selective doses (≤10mg) is lower-risk but not risk-free.

2. Serotonergic agents — serotonin syndrome risk

  • SSRIs, SNRIs, TCAs, triptans, tramadol, fentanyl, MDMA, lithium. Manageable with monitoring; usually used together in clinical practice when needed.

3. Acidifying / alkalinizing agents — alters d-amphetamine clearance

  • Sodium bicarbonate, antacids → raise urine pH → increase amphetamine half-life and AUC, risk of toxicity.
  • High-dose vitamin C, ammonium chloride → lower urine pH → reduce amphetamine half-life and AUC.
  • Practical implication: Dylan's V4 includes 500mg vitamin C — small effect, not concerning, but worth knowing if he ever stacks Vyvanse with bicarb supplementation (e.g., for athletic buffering).

4. Antihypertensives — reduced efficacy

  • Amphetamines counteract beta-blockers, ACE inhibitors, calcium channel blockers. Dylan: no current antihypertensives, not relevant.

5. CYP2D6 substrates — minimal interaction

  • d-amphetamine is a weak 2D6 substrate; not a strong inhibitor or inducer. Most interactions are minor.

6. Alcohol — additive cardiovascular stress; subjectively masks intoxication; risk of overconsumption. Dylan: zero alcohol baseline, non-issue.

7. Caffeine — additive HR/BP elevation, anxiety, sleep disruption. Dylan currently building caffeine baseline in V4 — would need to deconflict.

▸ Pharmacogenomics

CYP2D6 polymorphism: Modest effect. d-amphetamine clearance via 2D6 is a minor pathway; PMs have ~10-20% higher AUC. Less clinically dramatic than for many other 2D6 substrates. Dylan's CYP2D6 status will be inferable from 23andMe (June 2026 results) but unlikely to drive dosing changes.

COMT Val158Met: Predicts amphetamine response. Val/Val carriers (faster cortical DA clearance, "warriors") tend to benefit more from stimulants on cognitive tasks; Met/Met carriers (slower clearance, "worriers") often experience more anxiety and inverted-U dose response. Dylan's COMT status from 23andMe will inform interpretation.

DAT1 (SLC6A3) VNTR: 9-repeat carriers vs 10-repeat predict differential stimulant response in ADHD. Mainly relevant if formal ADHD treatment is on the table.

ADRA2A polymorphisms: Predict NE-mediated response. Mainly research-relevant.

RBC aminopeptidase polymorphisms: Theoretical — slower hydrolyzers would have lower exposure. Not clinically characterized as of 2026.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (brand Vyvanse) Local pharmacy $400-558/month uninsured; $30/month with Takeda copay savings card (commercial insurance only) High Brand consistently available 2025-2026 even when generics in shortage. Copay card excludes Medicare/Medicaid/TRICARE.
US Rx (generic LDX) Local pharmacy $200-360/month uninsured; $60-70/month with GoodRx coupons Medium Generic in active shortage Feb 2026 (Amneal, Hikma, Mallinckrodt, Solco — API supply issue). Mallinckrodt, Viatris, Hikma, Sun Pharma began shipping Aug 2023 after patent expiry Feb 2023.
US Rx telehealth Done, Cerebral, Klarity (varies by state) Variable; Schedule II tightening 2024-2026 Medium Schedule II requires synchronous video evaluation in most states post-Telehealth flexibilities expiration. Many telehealth platforms reduced or stopped Schedule II prescribing.
Takeda Help at Hand PAP Direct from Takeda Free brand Vyvanse if uninsured/underinsured + income threshold met High For qualifying patients only; income-based.
Indian online pharmacy Various LDX is not commonly stocked by Indian modafinil vendors; some stock IR Adderall analogs and dexamphetamine but lisdexamfetamine specifically is harder to find Variable Schedule II equivalent in India; legal import to US is a hard customs barrier (vs Schedule IV modafinil which is routinely tolerated). Not recommended.
Research-chem N/A N/A N/A Not available as RC; LDX is patent-derived prodrug, no gray-market analog.

For Dylan's case (off-label cognitive use, no diagnosis):

  • Sourcing solvable only via US Rx through legitimate ADHD evaluation. Without diagnosis, there's no comfortable gray-market path comparable to modafinil/Indian pharmacy. Telehealth Schedule II is increasingly gated. This sourcing friction is a secondary reason Vyvanse is a skip — even if the verdict were favorable, the path is harder than modafinil.
  • If diagnosis becomes clinically warranted (formal ADHD eval, BED diagnosis from clinician), insurance + Takeda copay card pathway is straightforward and affordable ($30-70/month).

Schedule II practical notes:

  • 30-day max prescription, no refills (post-DEA 2024 enforcement). Each refill requires new written/electronic prescription.
  • Pharmacy verification often required (some pharmacies refuse new patients on Schedule II).
  • Travel: US-internal only with prescription. International travel requires special documentation.
▸ Biomarkers to track (deep)

Baseline (before starting)

  • ECG — 12-lead resting ECG; screen for QTc prolongation, structural cardiac abnormalities, arrhythmia. Standard pre-amphetamine workup for adults.
  • Resting HR + BP — 3-day morning average, both arms. Amphetamines typically add 10-15 bpm and 5-10 mmHg systolic.
  • Body weight + body composition — DEXA or BIA if available. Track weight loss trajectory if any.
  • Sleep onset time + total sleep time — 2-week diary baseline (Dylan currently 2-3 AM bedtime, migrating). Critical baseline for comparing on-Vyvanse changes.
  • REM and deep sleep percentage — Oura/Whoop ring 2-week baseline. Stimulants reduce REM; quantification matters.
  • Anxiety and mood VAS — daily 1-10 scales for 2 weeks pre-dose.
  • Appetite VAS + actual caloric intake — 1-week food log baseline.
  • Cognitive performance battery — Cambridge Brain Sciences or similar online battery; baseline scores for working memory, sustained attention, response inhibition.
  • CBC + CMP — basic safety; covered in June 2026 panel.
  • TSH + fT4 — rule out untreated hyperthyroidism (would compound amphetamine effects dangerously).
  • Total testosterone, prolactin — baseline for HPA-axis and HPG-axis comparison; chronic high-dose stimulant use can suppress.
  • ALT/AST — minor stimulant hepatic load; baseline matters.
  • Urinary drug screen — confirms negative pre-Rx if needed for Schedule II workup.

During use

  • Weekly first 4 weeks: HR/BP morning + evening, sleep onset, weight, appetite VAS, anxiety VAS.
  • Monthly months 2-12: HR/BP, weight, sleep diary, mood/anxiety VAS, cognitive battery repeat.
  • Quarterly: ECG (especially first 6 months), CBC + CMP, ALT/AST, fasting glucose, lipid panel.
  • Annually: Full bloodwork, ECG, dental check (bruxism damage), reassessment of ongoing benefit > cost.
  • Symptom-driven: Any new chest discomfort, palpitations, syncope, severe headache, mood/personality change, peripheral coldness/numbness → same-day medical evaluation.

Post-cycle (if cycled)

  • Sleep architecture recovery (Oura/Whoop): expect REM rebound for 2-4 nights, then normalization.
  • Appetite/weight recovery: expect rebound +1-3 kg over 4-8 weeks during washout.
  • Mood/anhedonia post-cessation: monitor for 4-6 weeks; brief depressive episode common during withdrawal.
  • Cognitive baseline reassessment: subjective and via brain-training battery, after 4 weeks washout.
▸ Controversies / open debates Live debate

1. "Smoother PK = less harmful" — is this actually true for chronic users?

  • Yes, partially: lower abuse liability via parenteral routes is real and well-documented. Subjective comedown is genuinely milder. Less euphoria → less reinforcement → marginally lower addiction risk profile.
  • No, partially: Same active molecule (d-amphetamine) reaches the brain at clinically equivalent exposure. Receptor adaptation, tolerance, dependence, and brain-development effects are driven by AUC and chronic exposure, not peak shape. The prodrug is a delivery innovation, not a different drug. For Dylan's brain-development concern, the smoother PK provides little protection — the vulnerable window (PFC dopamine axon development through mid-20s) responds to total amphetamine exposure, not peak intensity. Animal studies haven't formally compared LDX to IR amphetamine on this endpoint, but mechanism predicts similar outcomes.
  • Reconciliation: "Smoother PK = somewhat lower harm at peak (sleep, anxiety, abuse liability) and somewhat lower harm in acute overdose. Same harm at chronic exposure level (tolerance, dependence, brain-dev impact)."

2. "Lower abuse liability" — what does this actually mean?

  • For IV/intranasal abuse: strong protective effect. IV LDX 50mg ≈ placebo for drug-liking. This is the marketing claim and it holds.
  • For oral abuse (taking too many pills): modest protective effect at most. Oral LDX produces drug-liking comparable to dose-matched oral d-amphetamine. The slower onset reduces "rush" but doesn't prevent escalation.
  • For physical dependence + withdrawal: no different from other amphetamines. Smoother taper at end of dose doesn't prevent the multi-day withdrawal syndrome after chronic use stops.
  • Practical implication for Dylan: If he were to use LDX, he'd be just as likely to develop dependence as on Adderall. The "lower abuse liability" framing applies to recreational tampering, not therapeutic-but-chronic exposure.

3. "Brain-development concern at 20 — overstated?"

  • Animal data: Robust and replicated. 2023 + 2025 papers show male adolescent rodent amphetamine exposure produces enduring PFC dopamine misrouting, dendritic remodeling, and inhibitory control deficits.
  • Translation uncertainty: Rodent adolescence ≈ ages 10-25 in humans; PFC matures into mid-20s. Direct translation is plausible but not proven. Sex-specificity (male only in rodents) tracks with human male-skewed stimulant abuse vulnerability.
  • Clinical data in humans age 20: Almost nonexistent for formal cognitive enhancement (off-label) populations. ADHD treatment cohorts show mixed signals — some show normalization of baseline ADHD-related abnormalities, some show persistent changes, none are randomized to placebo for ethical reasons.
  • Practical view: The mechanism is plausible enough + the population is vulnerable enough + the cognitive benefit at baseline is small enough that the precautionary verdict (skip until age 25-26) is the right call. This is exactly Dylan's calculus for Adderall, and Vyvanse doesn't escape it via prodrug delivery.

4. "But Vyvanse for BED is genuinely useful — why skip-for-now and not skip-permanent?"

  • Because verdict is profile-conditional. For a Dylan-archetype 20yo without ADHD or BED diagnosis, current verdict is SKIP-FOR-NOW. If clinical diagnosis emerges (formal ADHD eval, BED diagnosis), the verdict flips to STRONG-CANDIDATE — same compound, different decision context. The "for-now" carries the conditionality.

5. "Generic vs brand — equivalent?"

  • Phase 3 bioequivalence required for FDA generic approval. Reports from generic launch (Aug 2023) suggest mostly equivalent experience, with occasional anecdotal complaints about specific manufacturer batches (Hikma, SpecGx) feeling weaker. This is consistent with the 80-125% AUC tolerance window FDA allows. For most users, generic LDX is functionally equivalent.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW / MEDIUM CONFIDENCE. Best amphetamine profile in the class; same brain-development concern as Adderall (replicated 2023-2025) plus 12-14hr duration that conflicts with Dylan's late-chronotype sleep migration. Confirms encyclopedia entry from 2026-05-05 ("Best amphetamine if forced to pick one, but daily-use brain-dev concerns + appetite hit + sleep impact still apply. Skip for now.").
  • (No prior verdicts in compound-file format; encyclopedia entry was already SKIP-FOR-NOW.)
▸ Open questions / gaps Open
  1. 23andMe COMT, CYP2D6, DAT1 status (June 2026) — will calibrate predicted amphetamine response if verdict ever shifts.
  2. Formal ADHD evaluation — Dylan has not been clinically evaluated; current self-report is consistent with high-functioning baseline rather than ADHD. A formal eval would settle the verdict question. If diagnosis-positive, verdict flips to STRONG-CANDIDATE (and methylphenidate-class also opens up). Worth considering pre-baseline-bloodwork given the 12+ hour cognitive workload and ongoing stack questions.
  3. Bloodwork-driven decisions (June 2026) — baseline TSH, BP, HR, ECG before any amphetamine consideration regardless.
  4. Long-term cognitive trajectory in healthy 20yo daily users — no good prospective data exists for amphetamines in this population. Would require unethical RCT.
  5. MMA-specific cognitive risk overlay — d-amphetamine + subconcussive impact exposure. No data. Theoretical concern: amphetamine-driven catecholamine surge in the post-impact glutamate/oxidative environment could compound excitotoxic risk. Antioxidant + NAC coverage is a partial hedge but the underlying risk is unquantified.
  6. Vyvanse vs methylphenidate-class for ADHD-diagnosed Dylan-equivalent — methylphenidate has marginally lower brain-dev concern (no forced monoamine release, smaller animal model signal) but lower BED efficacy and different subjective profile. Decision-relevant only if ADHD diagnosis emerges.
  7. Modafinil vs Vyvanse as first-line for ADHD treatment in age 20 — modafinil has off-label efficacy data in adult ADHD (modest) and a much cleaner brain-dev profile. Some clinicians use modafinil first-line in young adults specifically to avoid amphetamine exposure during PFC maturation. Worth raising in any future Dylan ADHD eval.
▸ Sources (full, with our context)
Back to compact view